MiR-128 inhibitor decreased Aβ-mediated cytotoxicity by up-regulating PPAR-γ via inactivation of NF-κB in MCN and N2a cells, providing a new potential target in AD treatment. The gene discussed is NFKB1; the disease is Alzheimer disease.